Mittal Sajjan, Watson Henry G
Department of Haematology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK.
Br J Haematol. 2006 May;133(4):355-63. doi: 10.1111/j.1365-2141.2006.06023.x.
Recombinant activated factor VII (rVIIa) was initially used for the treatment of inhibitors in patients with haemophilia. However, its localised mode of action at sites of damage to the vessel combined with dramatic clinical observations in exsanguinating patients have resulted in huge interest in its use as a global haemostatic agent. Although it appears safe, with no obvious excess of thrombotic events, its use in assorted acquired bleeding disorders, especially those associated with the development of complex coagulopathies, such as in the post-trauma state, has proved to be less dramatic than hoped.
重组活化因子VII（rVIIa）最初用于治疗血友病患者体内的抑制物。然而，其在血管损伤部位的局部作用方式，以及在大出血患者身上显著的临床观察结果，引发了人们对将其用作全身性止血剂的极大兴趣。尽管它看起来安全，没有明显过多的血栓形成事件，但事实证明，将其用于各种获得性出血性疾病，尤其是那些与复杂凝血障碍发展相关的疾病，如创伤后状态，效果并不像预期的那么显著。
